Ann: Cell-Penetrating Phylomers Improve Delivery of Drugs-PYC.AX, page-20

Not sure what you mean re they didnt do the wider study because they came across their own myc inhibitors?
Are you aware of the history re development of omomyc and dr laura Soucek? I think the spelling is correct.

In essence pyc didnt stop because they came across their own inhibitors, the issue from the start was apparently that because Dr Soucek had published her findings on omomyc they were open to the public domain for trials and testing, but aparently she holds patents or similar so they cannot be used commercially i presume without license.

Dr Soucek had shown proof of concept with omomyc, but to date had been unable to develop the compound further as she could not get it to enter cells. Along came pyc and conjugated it with their cpp to show for the first time someone taking omomyc and actually showing its effectiveness if conjugated with a peoven cpp with endosomal escape.

This was the discovery that initially put a rocket under pyc shareprice a year or so ago. Since then it became apparent that while it proved the concept, we couldnt actually commercialise it because dr Soucek held the rights. Thus the next stage after such stunning results with breast cancer model was to find a new myc inhibitor we could use and actually commercialise. Hence the current search for our own.
Since then we also decided to change target from solid tumors to blood bourne cancers, hence my interest in the previous post.